aotccfteam.wordpress.com
December | 2011 |
https://aotccfteam.wordpress.com/2011/12
Archive for December, 2011. Question and Answer #1, Meghan Ramsay. AOTC program director, Meghan Ramsay, continues the conversation to ask a pertinent question. Meghan offers the 1st question from the symposium audience that wasn’t answered: Where does the VX-770 compound come from? Is it a natural occurring substance, and if so is it from a plant, fungus, etc? If not a plant how is it synthesized? Any thoughts on this? The Compound’s structure is represented as follows:. The John Hopkins University.
aotccfteam.wordpress.com
June | 2012 |
https://aotccfteam.wordpress.com/2012/06
Archive for June, 2012. Question From the Live Meeting. If I take Ivacaftor will I still need to take enzyme supplements or a high-calorie, high-fat diet? The John Hopkins University. School Of Medicine,. University School Of Medicine. An education grant from Vertex. Ahead of the Curve: Program Directory. Respiratory Medicine Resource Centre. AOTC: Genetics Revolution for the CF Care Team. Ahead of the Curve: Genetics Revolution for the CF Care Team. Blog at WordPress.com. Blog at WordPress.com.
appliedebm.wordpress.com
Depression: What is the next evidence-based step? | Applied evidence based laboratory
https://appliedebm.wordpress.com/2009/07/29/depression-what-is-the-next-evidence-based-step
Applied evidence based laboratory. Depression: What is the next evidence-based step? July 29, 2009 at 2:57 am ( Uncategorized. I will try to look for these questions and update the current post. 1 Is she on the appropriate first-step regimen for her symptoms. Among antidepressants which is the most effective? 2 What are other pharmacological and non-pharmacological approaches for her symptoms? 3 What is the next most appropriate and safe step in the management at this point. July 29, 2009 at 3:09 am.
hcv.hyperguides.com
Management of a Genotype 1a Patient with Relatively Mild Disease
http://www.hcv.hyperguides.com/initial-treatment-starting-therapy/2014/09_september/management-of-a-genotype-1a-patient-with-relatively-mild-disease
Initial Treatment: Starting Therapy. Retreatment if Prior Therapy has Failed. Extrahepatic Manifestations: Beyond the Liver. The Patient Toolkit helps to provide patients with the tools to better manage their health. To find out how to get this for your patients. Initial Treatment: Starting Therapy. This activity is expired and is no longer available for CME credit. Management of a Genotype 1a Patient with Relatively Mild Disease. Mark Sulkowski, MD; Nancy Reau, MD. Developed in collaboration with. After...
hcv.hyperguides.com
Decompensated Cirrhosis
http://www.hcv.hyperguides.com/unique-patient-populations/2014/09_september/decompensated-cirrhosis
Initial Treatment: Starting Therapy. Retreatment if Prior Therapy has Failed. Extrahepatic Manifestations: Beyond the Liver. The Patient Toolkit helps to provide patients with the tools to better manage their health. To find out how to get this for your patients. This activity is expired and is no longer available for CME credit. Mark Sulkowski, MD; Paul Kwo, MD; Norah A Terrault, MD, MPH. The patient with cirrhosis and decompensation is the special population that I would like to focus on today. Evaluat...
hcv.hyperguides.com
DAA Treatment Failures
http://www.hcv.hyperguides.com/retreatment-if-prior-therapy-has-failed/2015/01_january/daa-treatment-failures
Initial Treatment: Starting Therapy. Retreatment if Prior Therapy has Failed. Extrahepatic Manifestations: Beyond the Liver. The Patient Toolkit helps to provide patients with the tools to better manage their health. To find out how to get this for your patients. Retreatment if Prior Therapy has Failed. This activity is expired and is no longer available for CME credit. Jordan Feld, MD, MPH. Presented by the Johns Hopkins University School of Medicine. Developed in collaboration with. Hepatologist, Toron...
hcv.hyperguides.com
Patient with HCV Genotype 4
http://www.hcv.hyperguides.com/initial-treatment-starting-therapy/2015/01_january/patient-with-hcv-genotype-4
Initial Treatment: Starting Therapy. Retreatment if Prior Therapy has Failed. Extrahepatic Manifestations: Beyond the Liver. The Patient Toolkit helps to provide patients with the tools to better manage their health. To find out how to get this for your patients. Initial Treatment: Starting Therapy. This activity is expired and is no longer available for CME credit. Patient with HCV Genotype 4. Jordan Feld, MD, MPH; Nezam H. Afdhal, MD. Presented by the Johns Hopkins University School of Medicine. Harvar...
aotccfteam.wordpress.com
September | 2012 |
https://aotccfteam.wordpress.com/2012/09
Archive for September, 2012. Question Six, From Michael Boyle, M.D., F.C.C.P. Are there potential problems with taking ivacaftor with my other cystic fibrosis medications? I think the answer has two parts. The first deals with interactions with CF medications and the second is along the lines of medications I don’t need to take. You should also avoid certain herbal medications such as St. John’s wort, because those can also affect how the liver will clear ivacaftor. The second part of your question, shou...
ecysticfibrosisreview.org
eCysticFibrosis Review Newsletter, Volume 5, Issue 6
http://ecysticfibrosisreview.org/newsletters/2015/volume05_issue06.html
RECOMMEND TO A COLLEAGUE. VOLUME 5 - ISSUE 6. Improving digestive capabilities in nutritionally compromised patients with CF. Our guest author is Dr. Steven Freedman of Boston's Beth Israel Deaconess Medical Center and Harvard Medical School in Boston. After participating in this activity, the participant will demonstrate the ability to:. Explain exocrine pancreatic insufficiency with its effects on nutritional status. Identify patients with inadequate response to pancreatic enzyme replacement therapy.
ecysticfibrosisreview.org
eCysticFibrosis Review, Volume 5, Issue 4
http://ecysticfibrosisreview.org/newsletters/2015/volume05_issue04.html
RECOMMEND TO A COLLEAGUE. VOLUME 5 - ISSUE 4. Our guest author is Felix Ratjen, MD, from the Hospital for SickKids at the University of Toronto, in Toronto, Canada. After participating in this activity, the participant will demonstrate the ability to:. Explain the available options to treat early. Discuss whether treatment should be repeated in patients who develop recurrence of infection. Describe potential treatment options for patients failing eradication therapy. Felix Ratjen, MD. February 26, 2015.
SOCIAL ENGAGEMENT